SLE Epidemiology - 3) ESR Treatment o Severe flares IV...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
SLE Epidemiology 0.2% in the general population Female x9 Typically of child bearing age Commoner in afro-caribbeans, asians and HLA B8, DR2 or DR3 +ve. Diagnosis o Bloods – FBC (?anaemia, leukopenia, thrombocytopenia), U&E, LFTs, CRP usually normal o ANA – 95% +ve o Anti-dsDNA antibody – high titre highly specific but only present in 60% o ENA (anti-Ro etc) +ve in 20-30% o Rh F +ve in 40% o Raised ESR but normal CRP o Urine – for protein/casts need 4 or more features of SLE – e.g. ANA, rash, arthritis, lung change, bloods etc. .. In patient it is important to monitor the following: 1) Anti-dsDNA antibodies 2) reduced complement
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 2
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 3) ESR Treatment o Severe flares IV cyclophosphamide + prednisalone o Cutaneous symptoms reduce sun exposure. Topical steroids. o Maintenance NSAIDs + hydroxychloroquine (SE retinopathy) for joint and skin symptoms. Azathioprine/methotrexate can be used as steroid sparing agents. Prognosis o 80% survival at 15yrs. o Increased risk of cardiovascular disease and osteoporosis. Prevention Although not fully understood, because SLE is believed to have a genetic component it is difficult to prevent. Management consists of treating the symptoms as they becomes apparent....
View Full Document

Page1 / 2

SLE Epidemiology - 3) ESR Treatment o Severe flares IV...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online